Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta‐analysis of a shifting treatment paradigm

In younger patients with AML, HMA plus venetoclax yielded high response rates, MRD negativity, and a substantial proportion of patients proceeding to HSCT. These findings support HMA/venetoclax as an effective induction strategy in selected younger patients and provide a rationale for prospective randomized trials comparing this approach with IC-based regimens.